{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-020608","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.372853+00:00","generated_at":"2026-06-05T12:21:38.943493+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Beam Therapeutics Q4 net income $142.8M; cash $1.2B, runway to 2027","bullets":["Q4 net income $142.8M ($1.77 basic EPS) vs net loss $38.3M in Q4 2022; full-year net loss $132.5M vs $289.1M loss in 2022.","Cash, equivalents and marketable securities $1.2B at Dec 31, 2023, expected to fund operations into 2027.","BEAM-101 in SCD: sentinel cohort dosing and expansion cohort initiation H1 2024; initial clinical data expected H2 2024.","BEAM-302 for AATD Phase 1 trial initiation on track for H1 2024 pending CTA acceptance; BEAM-301 IND submission H1 2024.","R&D expenses rose to $140.1M Q4 (vs $86.3M) and $437.4M FY (vs $311.6M); G&A expenses $43.3M Q4 (vs $22.7M)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-020608","json":"https://secwatch.observer/filing/0000950170-24-020608.json","markdown":"https://secwatch.observer/filing/0000950170-24-020608.md","text":"https://secwatch.observer/filing/0000950170-24-020608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024020608/0000950170-24-020608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024020608/beam-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:21:38.943493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f39d4db6ca86aea0369d99cf545f92b7ef47e1f","claim":"Beam Therapeutics Inc. reported the year ended December 31, 2023 results: net income net loss attributable to common stockholders was $132.5 million, or $1.72 per share, for the year ended December 31, 202, EPS $1.72 per share.","evidence_excerpt":"net loss attributable to common stockholders was $132.5 million, or $1.72 per share, for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024020608/0000950170-24-020608-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"net loss attributable to common stockholders was $132.5 million, or $1.72 per share, for the year ended December 31, 202"},{"label":"EPS","value":"$1.72 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6582beb60a975fab452777eee9f4bf1ca9889f25","claim":"Beam Therapeutics Inc. reported the fourth quarter of 2023 results: net income Net income attributable to common stockholders was $142.8 million, or $1.77 per basic share and $1.73 per diluted share,, EPS $1.77 per basic share and $1.73 per diluted share.","evidence_excerpt":"Net income attributable to common stockholders was $142.8 million, or $1.77 per basic share and $1.73 per diluted share, for the fourth quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024020608/0000950170-24-020608-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Net income","value":"Net income attributable to common stockholders was $142.8 million, or $1.77 per basic share and $1.73 per diluted share,"},{"label":"EPS","value":"$1.77 per basic share and $1.73 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}